FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1987144470> ?p ?o ?g. }

• W1987144470 endingPage "S107" @default.
• W1987144470 startingPage "S101" @default.
• W1987144470 abstract "HER2 (neu, erbB-2), a receptor related to the human epidermal growth factor receptor, has now become more important as a predictive marker of treatment response. While the value and direction of the treatment/HER2 interaction may vary, depending on the agents, dose, or schedule of drug administration, there is little disagreement that HER2 testing is an important part of breast cancer evaluation. In 1998, trastuzumab (Herceptin) was approved for the treatment of HER2-positive metastatic breast cancer patients by the Food and Drug Administration of the USA. Patients with abnormal HER2 in their breast cancer cells (generally 2 or 3+ with the HercepTest, overexpression by other immunohistochemical assays or amplification by fluorescence in situ hybridization [FISH] assay) have demonstrated the greatest response to trastuzumab treatment. It is unclear which test (method, reagent, cut-off points, etc.) is best to use to evaluate HER2 for this purpose because parallel testing of the same cancers from patients who received trastuzumab has only recently been initiated and the data are limited. It is widely believed that breast cancers without HER2 alterations will not be responsive to trastuzumab, although a clinical trial to test this specific hypothesis has not been initiated. There are also concerns that clonal heterogeneity for HER2 within a tumor, or between primary and metastatic cancer foci, may affect treatment response; yet we do not currently evaluate these parameters. Consensus regarding the best methods, reagents, or cut-off points to define HER2 status for determining trastuzumab responsivity has not yet been reached. HER2 testing for other prognostic or predictive purposes, e.g. to determine whether patients are likely to respond to other agents, such as dose-intensive doxorubicin, may be less. Data from the Cancer and Leukemia Group B trial 8541 (companion 8869) suggest that, with proper controls in high-volume laboratories, many of the available methods produce comparable results." @default.
• W1987144470 created "2016-06-24" @default.
• W1987144470 creator A5013400628 @default.
• W1987144470 date "2001-01-01" @default.
• W1987144470 modified "2023-10-11" @default.
• W1987144470 title "HER2 – a discussion of testing approaches in the USA" @default.
• W1987144470 cites W1772131958 @default.
• W1987144470 cites W1922272927 @default.
• W1987144470 cites W1925485320 @default.
• W1987144470 cites W1976052438 @default.
• W1987144470 cites W1977221327 @default.
• W1987144470 cites W1986926262 @default.
• W1987144470 cites W2062713892 @default.
• W1987144470 cites W2101577390 @default.
• W1987144470 cites W2130923413 @default.
• W1987144470 cites W2141393790 @default.
• W1987144470 cites W2169782526 @default.
• W1987144470 cites W2328452031 @default.
• W1987144470 cites W2730858185 @default.
• W1987144470 cites W3128877721 @default.
• W1987144470 doi "https://doi.org/10.1093/annonc/12.suppl_1.s101" @default.
• W1987144470 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11521714" @default.
• W1987144470 hasPublicationYear "2001" @default.
• W1987144470 type Work @default.
• W1987144470 sameAs 1987144470 @default.
• W1987144470 citedByCount "33" @default.
• W1987144470 countsByYear W19871444702014 @default.
• W1987144470 countsByYear W19871444702015 @default.
• W1987144470 countsByYear W19871444702018 @default.
• W1987144470 countsByYear W19871444702022 @default.
• W1987144470 crossrefType "journal-article" @default.
• W1987144470 hasAuthorship W1987144470A5013400628 @default.
• W1987144470 hasBestOaLocation W19871444701 @default.
• W1987144470 hasConcept C121608353 @default.
• W1987144470 hasConcept C126322002 @default.
• W1987144470 hasConcept C143998085 @default.
• W1987144470 hasConcept C2775930923 @default.
• W1987144470 hasConcept C2777329042 @default.
• W1987144470 hasConcept C2779786085 @default.
• W1987144470 hasConcept C530470458 @default.
• W1987144470 hasConcept C71924100 @default.
• W1987144470 hasConceptScore W1987144470C121608353 @default.
• W1987144470 hasConceptScore W1987144470C126322002 @default.
• W1987144470 hasConceptScore W1987144470C143998085 @default.
• W1987144470 hasConceptScore W1987144470C2775930923 @default.
• W1987144470 hasConceptScore W1987144470C2777329042 @default.
• W1987144470 hasConceptScore W1987144470C2779786085 @default.
• W1987144470 hasConceptScore W1987144470C530470458 @default.
• W1987144470 hasConceptScore W1987144470C71924100 @default.
• W1987144470 hasLocation W19871444701 @default.
• W1987144470 hasLocation W19871444702 @default.
• W1987144470 hasOpenAccess W1987144470 @default.
• W1987144470 hasPrimaryLocation W19871444701 @default.
• W1987144470 hasRelatedWork W1964065629 @default.
• W1987144470 hasRelatedWork W1967506091 @default.
• W1987144470 hasRelatedWork W2001196910 @default.
• W1987144470 hasRelatedWork W2166148619 @default.
• W1987144470 hasRelatedWork W2167587342 @default.
• W1987144470 hasRelatedWork W2262572336 @default.
• W1987144470 hasRelatedWork W2333897269 @default.
• W1987144470 hasRelatedWork W2509762766 @default.
• W1987144470 hasRelatedWork W2989981638 @default.
• W1987144470 hasRelatedWork W67104293 @default.
• W1987144470 hasVolume "12" @default.
• W1987144470 isParatext "false" @default.
• W1987144470 isRetracted "false" @default.
• W1987144470 magId "1987144470" @default.
• W1987144470 workType "article" @default.